Zomedica Corp. (ZOM): Price and Financial Metrics

Zomedica Corp. (ZOM): $0.15

0.00 (3.40%)

POWR Rating

Component Grades

Momentum

C

Stability

F

Sentiment

Quality

F

ZOM Price/Volume Stats

Current price $0.15 52-week high $0.25
Prev. close $0.14 52-week low $0.12
Day low $0.14 Volume 4,103,897
Day high $0.15 Avg. volume 5,524,014
50-day MA $0.13 Dividend yield N/A
200-day MA $0.17 Market Cap 145.91M

ZOM Stock Price Chart Interactive Chart >

ZOM Stock Summary

  • For ZOM, its debt to operating expenses ratio is greater than that reported by just 9.04% of US equities we're observing.
  • ZOM's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 7.75% of US stocks.
  • Revenue growth over the past 12 months for ZOMEDICA CORP comes in at 42.44%, a number that bests 89.4% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to ZOMEDICA CORP are SIBN, MLSS, CDXC, AMRN, and SANM.
  • ZOM's SEC filings can be seen here. And to visit ZOMEDICA CORP's official web site, go to www.zomedica.com.

ZOM Valuation Summary

  • In comparison to the median Healthcare stock, ZOM's price/earnings ratio is 146.31% lower, now standing at -13.5.
  • Over the past 74 months, ZOM's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for ZOM.

Stock Date P/S P/B P/E EV/EBIT
ZOM 2023-12-29 8.2 0.8 -13.5 -10.3
ZOM 2023-12-28 8.6 0.8 -14.2 -10.8
ZOM 2023-12-27 8.8 0.8 -14.5 -11.1
ZOM 2023-12-26 9.1 0.8 -15.0 -11.5
ZOM 2023-12-22 8.9 0.8 -14.7 -11.3
ZOM 2023-12-21 8.9 0.8 -14.7 -11.2

ZOM Growth Metrics

    Its 3 year price growth rate is now at -36.09%.
  • Its 5 year cash and equivalents growth rate is now at -56.59%.
  • Its 5 year net cashflow from operations growth rate is now at -131.01%.
Over the past 46 months, ZOM's revenue has gone up $16,853,792.

The table below shows ZOM's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 16.85379 -14.18835 -18.31899
2022-06-30 12.10031 -16.41631 -18.83468
2022-03-31 7.869999 -14.10782 -18.23235
2021-12-31 4.133123 -14.27516 -18.38317
2021-09-30 0.052331 -12.05688 -19.26638
2021-06-30 0.029817 -12.72155 -17.90067

ZOM's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ZOM has a Quality Grade of F, ranking ahead of 3.62% of graded US stocks.
  • ZOM's asset turnover comes in at 0 -- ranking 441st of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows ZOM's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0 -0.393 -5.936
2021-03-31 0 0.599 -5.609
2020-12-31 0 NA -5.395
2020-09-30 0 NA -6.260
2020-06-30 0 NA -6.329
2020-03-31 0 NA -5.504

Zomedica Corp. (ZOM) Company Bio


Zomedica Pharmaceuticals Corp. operates as a veterinary pharmaceutical company in the United States. It focuses on the discovery, development, and commercialization of drugs, novel drug delivery systems, devices, and diagnostics for the health and wellness of companion animals, such as canine, feline, and equine. The company has a research collaboration agreement with Celsee Diagnostics, Inc. to test the feasibility of Celsee's liquid biopsy technology for veterinary application as a canine cancer diagnostics. Zomedica Pharmaceuticals Corp. was founded in 2015 and is based in Ann Arbor, Michigan.


ZOM Latest News Stream


Event/Time News Detail
Loading, please wait...

ZOM Latest Social Stream


Loading social stream, please wait...

View Full ZOM Social Stream

Latest ZOM News From Around the Web

Below are the latest news stories about ZOMEDICA CORP that investors may wish to consider to help them evaluate ZOM as an investment opportunity.

Zomedica Announces Expansion of Market Opportunity for TRUFORMA(R) Diagnostic Platform with Launch of Three New Assays for Commonly Performed Diagnostic Tests for Canine Gastrointestinal Disease

ANN ARBOR, MI / ACCESSWIRE / December 18, 2023 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced ...

Yahoo | December 18, 2023

Zomedica Announces Presentation of Clinical Data in Support of New Indications for PulseVet Shock Wave Therapy at Annual Meeting of American Association of Equine Practitioners

ANN ARBOR, MI / ACCESSWIRE / December 6, 2023 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced ...

Yahoo | December 6, 2023

Zomedica to Present at Noble Capital Markets' 19th Annual Emerging Growth Equity Conference

ANN ARBOR, MI / ACCESSWIRE / November 28, 2023 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for companion animals, today announced that ...

Yahoo | November 28, 2023

Zomedica to Present at the 35th Annual Piper Sandler Healthcare Conference

ANN ARBOR, MI / ACCESSWIRE / November 20, 2023 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for companion animals, today announced that ...

Yahoo | November 20, 2023

Zomedica Announces Record Third Quarter 2023 Financial Results: Revenue up 31% to $6.3 Million; 69% Gross Margin, and $118 Million in Liquidity, while Making Strategic Acquisitions of Structured Monitoring Products and Qorvo Biotechnologies

ANN ARBOR, MI / ACCESSWIRE / November 13, 2023 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for companion animals, today reported consolidated ...

Yahoo | November 13, 2023

Read More 'ZOM' Stories Here

ZOM Price Returns

1-mo 21.56%
3-mo -25.07%
6-mo -10.23%
1-year -27.92%
3-year -90.63%
5-year -57.14%
YTD -25.07%
2023 22.82%
2022 -46.82%
2021 32.91%
2020 -30.33%
2019 -73.09%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!